DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes
We show that DYRK1A inhibition restores the β cell mass and function in a preclinical model of T2D, leading to the improvement of body's global glucose homeostasis.
Authors
- Jamileh Movassat (ORCID: https://orcid.org/0000-0002-0314-1525)
- Emmanuel Deau (ORCID: https://orcid.org/0000-0001-6299-9946)
- Romane Bertrand
- Laurent Meijer (ORCID: https://orcid.org/0000-0003-3511-4916)
- Benjamin Uzan (ORCID: https://orcid.org/0000-0001-6323-5737)
- D. Picot (ORCID: https://orcid.org/0000-0002-9646-3135)
- Julien Dairou (ORCID: https://orcid.org/0000-0003-1767-0572)
- Mattias F. Lindberg (ORCID: https://orcid.org/0000-0002-9734-8163)
- Cécile Tourrel‐Cuzin (ORCID: https://orcid.org/0000-0002-5368-4018)
- Stéfania Tolu (ORCID: https://orcid.org/0000-0002-0928-5810)
- Ayoub Ouahab
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- ManRos Therapeutics (France) (FR)
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques (FR)
- Unit of Functional and Adaptive Biology (FR)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1016/j.molmet.2025.102242
- Citations
- 6
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 7.77
Funders
- Fondation Jérôme Lejeune
- Bpifrance
- Agence Nationale de la Recherche
- Centre National de la Recherche Scientifique
- HORIZON EUROPE European Innovation Council